Quick Answer
Inmune Bio, Inc. reported Stockholders Equity of $23.52 million for fiscal year 2025.
Inmune Bio, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $23.52M | -26.7% |
| 2024 | $32.10M | -14.0% |
| 2023 | $37.34M | -37.9% |
| 2022 | $60.10M | -25.1% |
| 2021 | $80.22M | +107.0% |
| 2020 | $38.75M | +64.1% |
| 2019 | $23.61M | +42.7% |
| 2018 | $16.54M | -8.6% |
| 2017 | $18.10M | +12233.6% |
| 2016 | -$149.2K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.38M | -34.4% | -12.1% |
| June 30, 2025 | $28.87M | -20.4% | -2.7% |
| March 31, 2025 | $29.67M | +5.1% | -7.6% |
| December 31, 2024 | $32.10M | -14.0% | -17.0% |
| September 30, 2024 | $38.67M | -12.0% | +6.6% |
| June 30, 2024 | $36.28M | -28.4% | +28.5% |
| March 31, 2024 | $28.22M | -49.0% | -24.4% |
| December 31, 2023 | $37.34M | -37.9% | -15.0% |
- Inmune Bio, Inc. showed a decrease of -26.7% in Stockholders Equity compared to the prior fiscal year.
- Over the 2016–2025 period, Inmune Bio, Inc.’s stockholders equity has grown by 15866.4% (from -$149.2 thousand to $23.52 million).
- The most recent figure is from Inmune Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: